Table 2 Comparison of the Health and Economic Impact of Scenarios including SF Antimalarials
From: Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model
| Â | Total Burden of Malaria with an SF Prevalence at 10.3% | Savings by eliminating 10.3% prevalence of SF Antimalarials | Total burden of SF Antimalarials with SF Prevalence of 19.1% | Antimalarial Resistance Scenario | ||||
|---|---|---|---|---|---|---|---|---|
Burden | 95% CI | Impact | % | Impact | %a | Impact | % Diff. | |
Average cases | 1,216,454 | (1,216,231 - 1,216,676) | Â | Â | Â | Â | Â | Â |
Average deaths | 2610 | (2598 - 2622) | 213 | 8.2% | 365 | 13.2% | 166 | 6.3% |
Average hospitalizations | 11,071 | (11,039 - 11,103) | 937 | 8.5% | 1643 | 14.0% | 1048 | 9.5% |
Average cases of NS | 295 | (291 - 299) | 9 | 3.1% | 11 | 3.8% | 19 | 6.5% |
Total economic impact | $141,470,907 | (141,037,214 - 141,904,600) | $8,541,887 | 6.0% | $14,465,329 | 9.8% | $9,662,235 | 6.8% |
Facility costs | $15,174,357 | (15,134,100 - 15,214,614) | $$411,098 | 2.7% | $637,725 | 4.1% | $1,266,646 | 8.3% |
Out-of-pocket costs | $11,699,978 | (11,536,334 - 11,863,623) | $423,151 | 3.6% | $478,061 | 4.1% | $677,144 | 5.8% |
Total productivity losses | $114,596,572 | (114,200,504 - 114,992,639) | $7,707,639 | 6.7% | $13,349,543 | 11.1% | $7,718,445 | 6.7% |
Short-term productivity losses | $25,162,247 | (25,090,781 - 25,233,713) | $531,091 | 2.1% | $1,021,167 | 4.0% | $2,053,261 | 8.2% |
Total lifetime productivity losses | $89,434,325 | (89,044,819 - 89,823,831) | $7,176,548 | 8.0% | $12,328,376 | 13.0% | $5,665,184 | 6.3% |